Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products.

Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

Type
Public
HQ
New York, US
Founded
2012
Size (employees)
22 (est)+100%
Website
axsome.com
Axsome Therapeutics was founded in 2012 and is headquartered in New York, US

Key People at Axsome Therapeutics

Herriot Tabuteau

Herriot Tabuteau

Chief Executive Officer
John Golubieski

John Golubieski

CFO
Robert Niecestro

Robert Niecestro

VP, Head of Regulatory Affairs

Axsome Therapeutics Office Locations

Axsome Therapeutics has an office in New York
New York, US (HQ)
25 Broadway

Axsome Therapeutics Data and Metrics

Axsome Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(8 m)

EBIT (Q1, 2017)

(7.7 m)

Market capitalization (25-Jul-2017)

109.2 m

Cash (31-Mar-2017)

45 m
Axsome Therapeutics's current market capitalization is $109.2 m.
USDFY, 2016

R&D expense

21.2 m

General and administrative expense

6.3 m

Operating expense total

27.5 m

EBIT

(27.5 m)

Net Income

(27.2 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

4.5 m5.3 m5.6 m6 m

General and administrative expense

1.4 m1.5 m1.6 m1.7 m

Operating expense total

5.9 m6.8 m7.2 m7.7 m

EBIT

(5.9 m)(6.8 m)(7.2 m)(7.7 m)

Net Income

(5.9 m)(12.7 m)(19.9 m)(8 m)
USDFY, 2016

Cash

36.6 m

Inventories

2.6 m

Current Assets

38 m

Total Assets

38.2 m

Accounts Payable

4.1 m

Current Liabilities

7.2 m

Total Liabilities

16.6 m

Additional Paid-in Capital

69.2 m

Retained Earnings

(47.6 m)

Total Equity

21.6 m

Financial Leverage

1.8 x
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

44.1 m38.8 m33.9 m45 m

Current Assets

45.1 m39.9 m34.8 m46.2 m

Total Assets

45.1 m40 m34.9 m46.4 m

Accounts Payable

1.8 m3 m3.9 m4.7 m

Current Liabilities

3.9 m5.1 m6.7 m8.4 m

Additional Paid-in Capital

65.9 m68 m68.5 m84.9 m

Retained Earnings

(24.7 m)(33.1 m)(40.3 m)(55.6 m)

Total Equity

41.2 m34.9 m28.2 m29.3 m

Financial Leverage

1.1 x1.1 x1.2 x1.6 x
USDFY, 2016

Net Income

(27.2 m)

Depreciation and Amortization

20.5 k

Inventories

(383.9 k)

Accounts Payable

2.2 m

Cash From Operating Activities

(21.3 m)

Cash From Investing Activities

(104.6 k)

Cash From Financing Activities

10 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.9 m)(12.7 m)(19.9 m)(8 m)

Depreciation and Amortization

2.1 k5.1 k10.7 k10.1 k

Accounts Payable

(61.9 k)1.1 m2 m659.5 k

Cash From Operating Activities

(3.9 m)(9.3 m)(14.1 m)(6.6 m)

Cash From Investing Activities

(10.7 k)(22.3 k)(98.5 k)(2.9 k)

Cash From Financing Activities

241.7 k7.1 m14.7 k15 m
Y, 2017

Financial Leverage

1.6 x

Axsome Therapeutics Market Value History

Axsome Therapeutics Company Life and Culture

You may also be interested in